Tota l Syn th esis of th e Bor on -Con ta in in g Ion Ca r r ier An tibiotic
Ma cr od iolid e Ta r tr olon B
J ohann Mulzer* and Markus Berger
Institut fu¨r Organische Chemie, Universita¨t Wien, Wa¨hringer Strasse 38, A-1090 Wien, Austria
johann.mulzer@univie.ac.at
Received September 24, 2003
The first total synthesis of the boron-containing macrodiolide antibiotic tartrolon B is reported in
full detail. Two convergent approaches to the target compound are described, the first of which
eventually failed, due to sensitive functionality. In the second, successful route the key step was a
stereoselective boron-mediated aldol addition of a bicyclic acetonide protected ketone to a diene-
aldehyde. In this case the synthesis could be completed without major problems, using a Yamaguchi
dimerization macrolactonization endgame.
In tr od u ction
C-2-OHs are shared by both coordination spheres. An-
other interesting feature is the planar conformation of
the E,Z-diene section, which makes the surface of the
molecule lipophilic. All oxygens are turned inside, to
make the core region strongly hydrophilic. In this way
the molecule appears optimized for carrying an ion
through a lipophilic membrane. In fact both tartrolon A
and B act as ion carriers and they are both active against
Gram positive bacteria with MIC values of 1 µg/mL. This
means that the presence of the boron is not required for
the antibiotic activity.
Tartrolon is structurally related to the antibiotics
boromycin,5 aplasmomycin,6 and borophycin7 which are
all feature a very similar C-1-C-7-region, possibly the
pharmacophore of the compounds (Figure 2). In contrast
to tartrolon, these antibiotics all exist only with the boron
core. Boromycin and aplasmomycin were both synthe-
sized a while ago, whereas no attempt toward synthesiz-
ing borophycin has yet been made.
Over the past decade we have been interested in the
total synthesis of structurally complex macrolides for
different reasons.1 One reason was that the molecular
architecture of these compounds poses a challenge to the
synthetic chemist; another reason was the enormous
potential of many of these compounds as potential drugs,
for instance as antibiotics or in tumor therapy. As an
example, we gave a full account of the first total synthesis
of tartrolon A and B,2 which are ion carrier antibiotics
of high activity.
The tartrolons were first isolated in 1994 by Ho¨fle and
Reichenbach from Myxobacterium Sorangium cellulosum
strain So ce678.3 The fermentation furnishes tartrolon
A (2) or B (1) (Figure 1) depending on the fermentation
vessel. Glass vessels provide boron and hence allow the
formation of 1, whereas in steel fermenters the boron-
free compounds 2 are formed as diastereomeric mixtures.
Alternatively, the boron can be incorporated into 2
chemically. This leads to a fixation of the variable
stereogenic center at C2 and forces 1 into a C2-sym-
metrical structure. The absolute and relative configura-
tion of tartrolone B has been clarified by a single-crystal
diffraction analysis4 of the potassium derivative (figure
in the Supporting Information). In this structure the
environment of both the boron and the potassium is
remarkable, as both atoms are close together, in form of
an inner ion pair. Boron forms a tetrahedral and potas-
sium an octahedral complex with macrolide oxygens. The
F ir st-Gen er a tion Retr osyn th esis
In view of the C2-symmetrical overall structure of the
target compounds our first retrosynthetic plan aimed for
a cylodimerization of the monomeric seco acid 3 under
Yamaguchi macrolactonization conditions (Scheme 1).
For the synthesis of 3 an aldol-type addition of ketone 5
to aldehyde 4 was envisaged as the key step. This kind
(5) (a) Hu¨ter, R.; Keller-Schierlein, W.; Knu¨sel, F.; Prelog, V.;
Rodgers, G. C.; Suter, P.; Vogel, G.; Za¨hner, H. J . Antibiot. 1967, 20,
1533. (b) Dunitz, J . D.; Hawley, D. M.; Miklos, D.; White, D. N. J .;
Berlin, Y.; Marusic, R.; Prelog, V. Helv. Chim. Acta 1971, 54, 1709.
Synthesis following that in: White, J . D.; Avery, M. A.; Choudhry, S.
C.; Dhingra, O. P.; Gray, B. D.; Kang, M.-c.; Kuo, S.-c.; Whittle, A. J .
J . Am. Chem. Soc. 1989, 111, 790.
(6) Okami, Y.; Okazaki, T.; Kitahara, T.; Umezawa, H. J . Antibiot.
1976, 29, 1019. Synthesis following that in: (a) Corey, E. J .; Pan, B.-
C.; Hua, D. H.; Deardorff, D. R. J . Am. Chem. Soc. 1982, 104, 6816.
(b) Corey, E. J .; Hua, D. H.; Pan, B.-C.; Seitz, S. P. J . Am. Chem. Soc.
1982, 104, 6818. (c) White, J . D.; Vedananda, T. R.; Kang, M.-c.;
Choudhry, S. C. J . Am. Chem. Soc. 1986, 108, 8105.
* Corresponding author. Phone: +431-4277-52190. Fax: +431-4277-
52189.
(1) Erythronolide B: Mulzer, J .; Kirstein, H. M.; Buschmann, J .;
Lehmann, Ch.; Luger, P. J . Am. Chem. Soc. 1991, 113, 910. Epothilone
B: Mulzer, J . Chem. Mon. 2000, 205. Laulimalide: Mulzer, J .; Oehler,
E. Chem. Rev. 2003, 103, 3753.
(2) Earlier reports: Mulzer, J .; Berger, M. Tetrahedron Lett. 1998,
39, 803-806. Mulzer, J .; Berger, M. J . Am. Chem. Soc. 1999, 121, 8393.
(3) (a) Schummer, D.; Irschik, H.; Reichenbach, H.; Ho¨fle, G. Liebigs
Ann. Chem. 1994, 283. (b) Irschik, H.; Schummer, D.; Gerth, K.; Ho¨fle,
G.; Reichenbach, H. J . Antibiot. 1995, 48, 26.
(4) Schummer, D.; Schomburg, D.; Irschik, H.; Reichenbach, H.;
Ho¨fle, G. Liebigs Ann. Chem. 1996, 965.
(7) Hemscheidt, T.; Puglisi, M. P.; Larsen, L. K.; Patterson, G. M.
L.; Moore, R. E.; Rios, J . L.; Clardy, J . J . Org. Chem. 1994, 59, 3467.
10.1021/jo035391p CCC: $27.50 © 2004 American Chemical Society
Published on Web 01/13/2004
J . Org. Chem. 2004, 69, 891-898
891